December 20, 2013
The challenges faced by a number of the processors and reactors involved in the production of Molybdenum-99 (Mo-99) continue, ultimately affecting, at times, the supply of Mo-99 to the global nuclear medicine industry. Given the evolving situation, it is premature to project supply beyond January. Mallinckrodt recognizes the effect of these challenges in the instances when you and the patients you serve are affected.
Click here for the full letter from Mallinckrodt Pharmaceuticals.